BioWorld

April 15, 2002

Ribapharm Enters Record Books With Long-Awaited $260M IPO

It’s been a long time coming, but well worth the wait. Ribapharm Inc., having filed for its initial public offering in June 2000, got the deal done Friday, pricing 26 million shares at $10 apiece, raising $260 million and entering biotechnology’s IPO record book. (BioWorld Today) Read More

Ligand, Lilly Extend Collaboration In PPARs For Multiple Indications

Suppressing Tumor Suppressors, Methylation, Epigenetic Silencing Play Roles In Colon Cancer Cells

NIH Enters Agreement For Access To Six Stem Cell Lines

Bavarian Nordic, PowderJect Collaborate On Vaccine Delivery

Correction

Other News To Note

Today's news in brief

BioWorld

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...